A Study of Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis

Overview

About this study

The purpose of this study is to learn more about the role of etanercept alone or in combination with methotrexate on disease activity in subjects with psoriatic arthritis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria

  • Must have a diagnosis of PsA by the Classification Criteria for Psoriatic Arthritis (CASPAR)
  • Has ≥ 3 tender and ≥ 3 swollen joints at screening and at baseline
  • Has an active psoriatic skin lesion
  • Is naïve to etanercept and any other biologic for the treatment for PsA or Psoriasis
  • Has no prior use of methotrexate for PsA
  • Has no history of tuberculosis
  • Has a negative test for tuberculosis, hepatitis B and C

Exclusion Criteria

  • Has known history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes, including Human Immunodeficiency Virus infection
  • Has any active infection (including chronic or localized infections) for which anti-infectives were indicated within 4 weeks prior to the first dose of investigational product
  • Has a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to the first dose of investigational product

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Eric Matteson, M.D.

Closed for enrollment

More information

Publications

  • To evaluate the efficacy of etanercept and methotrexate as monotherapies and as combination therapy in subjects with active psoriatic arthritis (PsA). Read More on PubMed

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20192055

Mayo Clinic Footer